Ascendis Pharma A/S
ASND
$190.91
-$5.07-2.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 68.84% | -42.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 68.84% | -42.69% | |||
| Cost of Revenue | 93.61% | 23.32% | |||
| Gross Profit | 63.64% | -48.48% | |||
| SG&A Expenses | 14.80% | 24.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.91% | 16.72% | |||
| Operating Income | 45.20% | -26,959.42% | |||
| Income Before Tax | 59.65% | -147.08% | |||
| Income Tax Expenses | 291.15% | -3.47% | |||
| Earnings from Continuing Operations | 55.72% | -142.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.72% | -142.84% | |||
| EBIT | 45.20% | -26,959.42% | |||
| EBITDA | 47.36% | -6,185.88% | |||
| EPS Basic | 56.04% | -141.89% | |||
| Normalized Basic EPS | 59.94% | -146.11% | |||
| EPS Diluted | 56.04% | -141.89% | |||
| Normalized Diluted EPS | 62.11% | -146.11% | |||
| Average Basic Shares Outstanding | 0.73% | 0.39% | |||
| Average Diluted Shares Outstanding | 6.49% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||